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Abstract
Background: The defective glycosylation of α-dystroglycan is associated with a group of muscular dystrophies that
are collectively referred to as the secondary dystroglycanopathies. Mutations in the gene encoding fukutin-related
protein (FKRP) are one of the most common causes of secondary dystroglycanopathy in the UK and are associated
with a wide spectrum of disease. Whilst central nervous system involvement has a prenatal onset, no studies have
addressed prenatal muscle development in any of the mouse models for this group of diseases. In view of the
pivotal role of α-dystroglycan in early basement membrane formation, we sought to determine if the muscle
formation was altered in a mouse model of FKRP-related dystrophy.
Results: Mice with a knock-down in FKRP (FKRPKD) showed a marked reduction in α-dystroglycan glycosylation
and reduction in laminin binding by embryonic day 15.5 (E15.5), relative to wild type controls. In addition, the total
number of Pax7+ progenitor cells in the FKRPKD tibialis anterior at E15.5 was significantly reduced, and myotube
cluster/myofibre size showed a significant reduction in size. Moreover, myoblasts isolated from the limb muscle of
these mice at E15.5 showed a marked reduction in their ability to form myotubes in vitro.
Conclusions: These data identify an early reduction of laminin α2, reduction of myogenicity and depletion of
Pax7+ progenitor cells which would be expected to compromise subsequent postnatal muscle growth and its
ability to regenerate postnatally. These findings are of significance to the development of future therapies in this
group of devastating conditions.
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Background
Dystroglycan is a key component of the dystrophin-
glycoprotein complex (DGC) which connects the extracel-
lular matrix to the muscle fibre cytoskeleton [1]. It is com-
posed of two non-covalently associated sub-units, α and β.
α-dystroglycan is subject to extensive O-mannosylation
which is responsible for binding to extracellular matrix
proteins such as laminin, perlecan and agrin [2], in
addition to neurexin in the brain [3], pikachurin in the eye
[4] and most recently, slit [5] in the nervous system. β-
dystroglycan is a transmembrane protein which links
α-dystroglycan to dystrophin and utrophin on the
cytoplasmic side of the sarcolemma [6]. The abnormal
glycosylation of this protein is the underlying cause
for a subset of inherited autosomal recessive muscular
dystrophies, collectively known as the secondary dys-
troglycanopathies [7, 8].
To date, up to 18 genes have been implicated in the
secondary dystroglycanopathies. Mutations in the fukutin-
related protein (FKRP) gene are a common cause of
secondary dystroglycanopathy and are associated with a
wide range of clinical features, including severe structural
brain involvement resembling Walker–Warburg syn-
drome (WWS) and muscle-eye-brain disease (MEB), to
congenital muscular dystrophy without brain involvement
(MDC1C) and adult-onset limb-girdle muscular dystrophy
(LGMD2I) [9–23]. LGMD2I represents the most common
form of LGMD in the UK [8]. Phenotypic variability is not
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unique for mutations in the FKRP gene, and a similar
spectrum of clinical involvement has been observed for
most of the other dystroglycanopathy genes [24].
Muscle differentiation is accompanied by marked
changes in the glycosylation of α-dystroglycan [25, 26]
mediated at least in part by the coordinated upregula-
tion of like-acetylglucosaminyltransferase (LARGE), a
bifunctional glycosyltransferase which is known to be
responsible for the post-translational addition of the poly-
saccharide repeating unit [-3-xylose-α1,3-glucuronic acid-
β1-] on α-dystroglycan [27]. Blocking this process leads to
a less compact basement membrane, immature neuro-
muscular junctions and abnormal muscle predisposed to
dystrophy [27]. However, the impact of altered/reduced
glycosylation of α-dystroglycan on prenatal muscle de-
velopment has not yet been evaluated despite the im-
plications that this might have for muscle mass in
dystroglycanopathy patients [28].
Myogenesis in the mouse may be divided into two
main stages; the first is referred to as primary (embry-
onic) myogenesis. During this phase, primary myotubes
are generated through myoblast proliferation and fusion.
The primary myotubes make an appearance between
E11 and E14 in mice, extending from tendon to tendon,
and the majority initially expresses the slow myosin
heavy chain (MHC) although expression may switch
later depending on the individual muscle [29]. Groups of
primary myotubes are initially surrounded by a single
basement membrane but subsequently separate and be-
come surrounded by their own basement membrane
[30]. The primaries act as a scaffold for subsequent gen-
erations of myoblasts that fuse to form secondary, and
in the larger muscles, tertiary myotubes [30]. The sec-
ondary myogenesis in the mouse takes place between
E14.5 and E17.5. The early secondary myotubes initially
form close to the neuromuscular junctions of the primary
[31]. The majority of fibres in the adult muscle originate
from the secondary and tertiary myotubes, and final fibre
number is determined around the time of birth [30].
We previously generated a FKRP-deficient mouse
which has a knock-down in the expression of the FKRP
gene (FKRPKD). These mice die around the time of birth
or within the first 24 h due to central nervous system in-
volvement [32, 33] since restoration of FKRP in all
neural tube-derived cells prevents perinatal lethality
[34]. In the present work, we used the FKRPKD mouse to
examine the role of α-dystroglycan glycosylation on
primary and secondary myogenesis. On the basis of the
previous work which suggests that a deficiency of fuku-
tin is associated with an impairment of myoblast precur-
sor cell proliferation, differentiation and muscle
regeneration [35], our hypothesis was that a reduction in
α-dystroglycan glycosylation would be associated with a
reduction in Pax7+ progenitor cells. Since FKRPKD mice
are not associated with an overt muscle pathology at
birth [32], we further hypothesized that the initial diver-
gence between FKRPKD and wild type would take place
during the later stages of muscle development. An evalu-
ation of the tibialis anterior (TA) and extensor digitorum
longus (EDL) at E15.5 and P0 (at birth) indicated that
both these muscles showed a reduction in α-
dystroglycan glycosylation and laminin binding in the
FKRPKD compared to wild types. Moreover, there was a
significant reduction in myotube cluster size at E15.5 in
the TA, implying that the secondary myogenesis was al-
tered. This was further supported by the finding that
there was a reduction in the myogenicity of cultures de-
rived from the mice at this age. Associated with this was
a significant reduction in the number of Pax7+ progeni-
tor cells at E15.5 and P0 in the TA. Whilst differences
were also noted in the EDL, the data did not achieve
statistical significance. Indeed, this might be expected
given that individual muscles often differ with respect to
their stage of development during embryogenesis. Over-
all, these findings suggest that defects in α-dystroglycan
glycosylation are associated with an early reduction in
the number of Pax7+ progenitor cells which would be
expected to compromise subsequent postnatal muscle
growth and regeneration.
Methods
Mice
All animal experiments were carried out under license
from the Home Office (UK) in accordance with The An-
imals (Scientific Procedures) Act 1986 and were ap-
proved by the Royal Veterinary College ethics and
welfare committee. The FKRP-NeoTyr307Asn (FKRPKD) has
a neomycin selection cassette in intron 2 and a missense
mutation in exon 3. The missense mutation (Tyr307Asn)
has previously been shown to result in no discernable
phenotype in the mouse; however, the presence of the
neomycin selection cassette results in a 60–80 % reduc-
tion in FKRP transcript levels [32, 36]. The morning of
identification of the copulatory plug was taken to be
E0.5. On E15.5 of gestation, the dam was euthanised by
atlanto-occipital dislocation. The embryos were then dis-
sected out of the uterus and together with pups at P0
sacrificed by cervical dislocation. Tail samples from each
were collected and retained for genotyping. The hin-
dlimbs from at least five embryos/pups in each group
were dissected, mounted in OCT and snap-frozen in
liquid nitrogen-cooled isopentane. Generally, all mea-
surements were undertaken on the same embryos/pups;
however, limited quantities of the tissue sometimes ne-
cessitated additional embryos/pups being included in the
analyses; hence, the n values differ between some data
sets. All tissue was stored at −80 °C prior to sectioning
with a Bright cryostat. Serial 10 μm cryosections were
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taken from the entire lower hindlimb and sections of the
midbelly region of the EDL and TA selected for
immunolabelling.
Genotyping
Genotyping was carried out by PCR using three primers.
Primers: FKRP forward (GTTGTGCTTAAACCACCTTC)
and FKRP reverse (CTAGGAGGTTGAGGATGATGG)
were used for detecting the wild type allele, and FKRP-Neo
forward (GGTGGGATTAGATAAATGCC) and FKRP re-
verse were used for detecting the mutant allele.
Alcian blue/alizarin red staining
Alcian blue stains the cartilage (blue) whilst alizarin red
stains the ossified bone (red). Newborn (P0) pups were
culled by cervical dislocation, and the skin, viscera and
adipose tissue were removed. Bodies were placed in acet-
one for 2 days and then stained with 0.3 % (w/v) alcian
blue 8GS in 70 % ethanol (1 volume), 0.1 % (w/v)
alizarin red S in 95 % ethanol (1 volume), acetic acid
(1 volume) and 70 % ethanol (17 volumes). Filtered stock
solutions of alizarin red and alcian blue were made in ad-
vance. The following staining samples were washed in dis-
tilled water and then cleared in 1 % (w/v) solution of
potassium hydroxide for 12–48 h. Once the skeleton was
clearly visible, samples were cleared with 20, 50 and 80 %
glycerol in 1 % potassium hydroxide. Once cleared, all
samples were stored in 100 % glycerol.
Measurements of tibia and femur length by CT scan
Tibia and femur length was measured using micro-
computed tomography data of scanned newborns.
Newborn (P0) pups underwent 180° scans in a Skyscan
1172F scanner with a 10 MP X-ray detector (Bruker,
Kontich, Belgium). The X-ray source settings were at
40 kV and 200 mA, a 0.5-mm aluminium filter was
used with a 6-μm pixel size and an exposure time of
2300 ms. Projection images were reconstructed into
tomograms using NRecon (Skyscan) and then volume
rendered using CTVox (Skyscan) to give 3D models
which were measured using ImageJ [37].
Immunohistochemistry
Prior to immunolabelling, all slides were allowed to air-
dry. Unfixed sections were used throughout this study
with the exception of the Ki67 (DAKO), Pax7 (DSHB)
and IIH6 (Millipore) where sections were fixed in 4 %
paraformaldehyde (PFA) for 10 min, washed and per-
meabilised in 0.1~0.5 % triton in phosphate-buffered so-
lution (PBS) for 10–15 min. After washing, sections
were blocked in 10 % horse serum (PAA) in PBS (10 %
horse serum in PBS + 5 %BSA for IIH6) for 1 h prior to
incubation with adequate primary antibodies at room
temperature for 1 h (with the exception of the IIH6
antibody which was incubated overnight at 4 °C). To
minimise background staining when labelling for Pax7
and Ki67, the Mouse On Mouse immunodetection kit
was used (Vector Laboratories). All the other primary
antibodies (listed in Table 1) were applied to the sec-
tions after blocking in 10 % horse serum in PBS for
1 h at room temperature. All dilutions were made up
with PBS. The primary antibodies were incubated for
1 h at room temperature and the secondary antibodies
for 30 min at room temperature followed by another
15 min incubation with streptavidin 488/594 (room
temperature, Invitrogen) if a biotinylated secondary
antibody was used. Nuclei were labelled with Hoechst
33342 trichloride (DAPI) (Sigma-Aldrich), which was
diluted at 1:2000 with PBS. Controls for background
included an incubation with the secondary antibody. In
between all incubations, slides were washed in PBS
three times for 5 min each time. The slides were then
mounted with cover slides using Hydromount (Diag-
nostic laboratories, UK). Immunolabelled slides were
viewed under epifluorescent microscope (Leica
DM4000B interfaced with a Zeiss AxioCam MRm
monochrome camera.
Table 1 Antibodies used in immunohistochemistry
Antibodies Manufacturer Dilution Species
α-dystroglycan (IIH6) Millipore 1:200 Mouse (IgM)
β-dystroglycan Vector laboratories 1:20 Mouse
Pax7 Developmental Studies
Hybridoma Bank (DSHB)
1:50 Mouse
Ki67 DAKO 1:200 Rat
Type IV collagen Invitrogen 1:50 Goat
Perlecan Invitrogen 1:5000 Rat
Pan Laminin Sigma 1:200 Rabbit
Laminin α1 Gift from Professor
Madeleine Durbeej-Hjalt
1:100 Rat
Laminin α2 Enzo 1:200 Rat
Laminin α4 R&D systems 1:200 Goat
Laminin α5 Gift from Madeleine
Durbeej-Hjalt
1:200 Rabbit
Laminin β1 Millipore 1:2000 Rat
Laminin γ1 Millipore 1:2000 Rat
Fast myosin heavy
chain
Leica 1:20 Mouse
Slow MHC Millipore 1:200 Mouse
Developmental MHC Leica 1:20 Mouse
Mandys1 (dystrophin) Gift from Professor
Glenn Morris
1:20 Mouse
Myogenin Santa Cruz 1:200 Rabbit
MyoD Santa Cruz 1:200 Rabbit
Kim et al. Skeletal Muscle  (2016) 6:3 Page 3 of 15
Western blotting and laminin overlay assay
The muscle was dissected from the entire limb and cell
proteins extracted in lysis buffer, radio immunoprecipita-
tion assay (RIPA) buffer consisting of 50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 % Triton X-100,
0.1 % SDS and 1 mM azide, plus a cocktail of protease
inhibitors (Roche). Protein concentration was measured
using the BCA Protein Assay Kit (Thermo Scientific
Pierce). A 30 μg of soluble proteins was resolved using a
NuPAGE Pre-cast gel (3–8 % Tris-acetate; Invitrogen) and
then transferred electrophoretically to Hybond-PVDF
membrane (GE Healthcare, UK). PVDF membrane were
blocked in 5 % dried non-fat milk in phosphate-buffered
saline buffer, and then probed with the primary antibodies:
anti-mouse α-DG IIH6 (Millipore, UK, cat, 05-593) anti-
mouse β-DG (Vector Labs, UK), at room temperature for
1 h. After washing, they were incubated with the appropri-
ate horseradish peroxidase (HRP)-conjugated secondary
antibody for 1 h: anti-mouse-IgM or anti-mouse-IgG
(both from Jackson ImmunoResearch, USA). After wash-
ing, the membranes were visualized using enhanced
chemiluminescence (ECL) substrate (Thermo scientific
Pierce) and imaged using a Bio-Rad ChemiDoc MP
imaging system.
For the laminin overlay assay, PVDF membranes were
blocked for 1 h in laminin-binding buffer (LBB; 10 mM
triethanolamine, 140 mM NaCl, 1 mM MgCl2, 1 mM
CaCl2, pH 7.6) containing 5 % non-fat dry milk followed by
incubation of 1 μg/ml mouse Engelbreth–Holm–Swarm
(EHS) laminin protein (Invitrogen) in LBB overnight on a
roller at 4 °C. The membranes were washed and incubated
with rabbit anti-laminin (Sigma) followed by HRP-anti-
rabbit IgG (Jackson ImmunoResearch). Blots were visual-
ized using enhanced chemiluminescence (ECL) substrate
(Thermo scientific Pierce) and imaged using a Bio-Rad
ChemiDoc MP imaging system.
Tissue culture
All muscles were removed from the limbs of E15.5 em-
bryos and digested with freshly made enzyme solution.
The enzyme solution consisted of phosphate-buffered
saline (PBS; Gibco) mixed with 0.5 mg/ml w/v collage-
nase (Sigma–Aldrich), 1 mg/ml w/v Bovine serum albu-
min (BSA; Sigma–Aldrich) and 6 % v/v Trypsin-ethylene
diamine tetra acetic acid (EDTA; Invitrogen). This was
incubated with the muscle following trituration for
30 min at 37 °C. After 30 min, the enzyme solution was
removed and discarded in order to dispose of fibroblasts.
The second and third digestions were then undertaken,
and the cells from each were pooled and placed in
growth medium (GlutaMAX DMEM (Gibco)) contain-
ing 1 % penicillin–streptomycin–neomycin (PSN; Gibco)
and 20 % fetal bovine serum (FBS). This cell solution
was then plated onto Matrigel (1 mg/ml) coated plate or
chamber slides directly to facilitate proliferation. Differ-
entiation was initiated by switching to 10 % FBS after
48 h (Gibco).
Quantification and statistical analysis
ImageJ was used to measure myotube clusters/fibre size
[37]. This was done manually using a light pen on im-
ages (resolution 150 pixels/in.) at either ×10 or ×20
magnification.
The expression of the transcription factor Pax7 was
assessed across the entire cross-sectional area of the
muscle. The quantification of the number of Pax7+ nu-
clei was expressed as the number per fibre in the TA
and EDL at E15.5 and P0.
Data were analysed using GraphPad Prism 5 software.
Confirmation of normality was undertaken using Kol-
mogorov–Smirnov test; unpaired t tests were performed
to compare wild type and mutant animals and ANOVA
for comparisons between wild type, heterozygotes and
mutants.
Results
Litter size and longitudinal growth were not altered in
the newborn FKRPKD mice
A comparison of alcian blue/alizarin red-stained wild
type and FKRPKD pups at P0 which showed the extent
of the ossified bone (red) and cartilage (blue) indicated
no significant differences with respect to skeletal devel-
opment between the two genotypes (Fig. 1a, wild type
and 1B FKRPKD). Measurements of the tibia and femur
using computed tomography as an indirect measure-
ment of muscle length showed no significant differences
between WT and FKRPKD (Fig. 1c). Body weight was sig-
nificantly lower in the FKRPKD at P0 relative to wild type
as previously reported, whilst litter size influenced this
parameter, overall litter size was not significantly differ-
ent between WT and FKRPKD.
A reduction in α-dystroglycan glycosylation does not alter
muscle patterning but is associated with an alteration in
laminin immunobinding by E15.5 and P0
Transverse sections through the entire lower hindlimb
at E15.5 and P0 of both FKRPKD and wild type immuno-
labelled for slow myosin heavy chain showed no alter-
ation in muscle patterning (Fig. 1d). In the tibialis
anterior (TA) and extensor digitorum longus (EDL), a
population of the larger primary myotubes could be
clearly identified. The majority of these primaries at
E15.5 were surrounded by smaller secondaries forming
myotube clusters which were enclosed within a single
basement membrane delineated by immunolabelling for
laminin, perlecan or collagen type IV. In wild type mice
immunolabelling for IIH6 (identifies the laminin binding
epitope of α-dystroglycan) followed that of other
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basement membrane markers (Fig. 2a). However, in the
FKRPKD at E15.5 and P0, although there was some vari-
ation between pups most likely due to the model being a
hypomorph, overall, there was a marked reduction in
IIH6 immunolabelling. These observations therefore in-
dicate that glycosylated α-dystroglycan is present from
the earliest stages of myotube formation in wild type
mice and is markedly reduced in the FKRPKD. However,
β-dystroglycan was unchanged between wild type and
FKRPKD as was dystrophin which marks the sarcolemma
of both primary and the early secondaries (Fig. 2a). Per-
lecan, an additional ligand of α-dystroglycan also
dependent on its proper glycosylation showed no differ-
ence between mutant and wild type (Fig. 2a).
In order to make an assessment of the relative molecu-
lar mass and laminin binding properties during muscle
develoImmunolabelling using an antibodypment, we
next compared α-dystroglycan at E15.5 and P0 in wild
type and FKRPKD mice using Western blotting. This
showed that, as has been previously observed during de-
velopment of the chick and human muscle, the relative
molecular mass of α-dystroglycan in wild type muscle is
reduced in fetal relative to the adult mouse muscle
(Fig. 3b) [25, 26]. Protein loading was assessed using
Amido Black staining of the PVDF membrane (Fig. 3a).
In agreement with the immunolabelling, only residual
IIH6 labelling was observed following Western blot ana-
lysis of FKRPKD at either E15.5 or P0. A laminin overlay
assay further showed that whilst α-dystroglycan was able
to bind laminin at both E15.5 or P0 in the wild type, no
binding was observed in the FKRPKD (Fig. 3c). Taken
overall, these observations imply that α-dystroglycan gly-
cosylation plays a role in basement membrane assembly
during the early stages of fibre formation.
Expression of laminin α2 is reduced early during
secondary myogenesis
We next examined the impact of reduced α-dystroglycan
on laminin expression. Laminin α-chains interact with
dystroglycan via their LG domains although each iso-
form may bind with different affinities. Using chain-
specific antibodies, we labelled transverse sections of the
tibialis anterior and extensor digitorum longus for lam-
inin α1, α4, α5, β1 and γ1. This showed that laminin α2
was reduced in the FKRPKD relative to wild type at both
E15.5 and P0 (Fig. 2b). Laminin α1 immunolabelling was
only observed at the dermal–epidermal junction in the
skin and myotendinous junction. Whilst no clear differ-
ences were seen in the muscle from either FKRPKD or
wild type with respect to laminin α1 (data not shown),
expression was reduced in the skin of the FKRPKD at
E15.5, a feature that was less pronounced by the time of
birth (Fig. 2b). These mice however, showed no other
noticeable skin defects. A subtle reduction was seen with
β1 in the FKRPKD although this would need to be con-
firmed by Western blot. Immunolabelling for laminin
α5, α4 and γ1 was however, equivalent to the wild type
(Fig. 4). These observations imply that at these stages of
Fig. 1 Skeletal development, body weight and skeletal muscle development. A comparison of alizarin blue staining of wild type (a) and FKRPKD
(b) pups at P0 indicated no differences with respect to skeletal development. c Body weight was significantly lower in FKRPKD (p = 0.0069) relative
to wild type; there was no significant difference in body weight between wild type and heterozygous mice. Tibia/femur length was measured
using micro-computed tomography and showed no significant differences between FKRPKD and wild type at P0. Data was analysed by one-way
ANOVA. d Transverse sections of the hindlimb muscle at E15.5 and P0 immunolabelled for slow myosin heavy chain. The proportion of myotubes
expressing slow myosin heavy chain was similar between FKRPKD and wild type. At P0, fewer myotubes/fibres expressed slow myosin, with those
still positive distributed in the superficial area of the TA and EDL. In the soleus which is a slow postural muscle in the adult, slow myosin continued to
be expressed in most of myotubes/fibres
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Fig. 2 (See legend on next page.)
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Fig. 2 Immunolabelling of α- and β-dystroglycan, dystrophin and perlecan. a Transverse sections through the TA and EDL at E15.5 and P0
immunolabelled for α- (A-D) and β-dystroglycan (E-H), dystrophin (Mandys1, I-L) and perlecan (M-P). α-dystroglycan (IIH6) showed a clear
delineation of the basement membrane around clusters of primary and secondary myotubes at E15.5 (A) and individual muscle fibres at
P0 (C), although some clusters are still evident. There was an almost total absence of IIH6 in the FKRPKD at both time points (B,D).
Residual staining of the neuromuscular junction in the FKRPKD at P0 is shown in D as an inserted image. β-dystroglycan, dystrophin and
perlecan immunolabelling were not markedly different between FKRPKD and wild type at either time point (E-P)
Fig. 3 IIH6 Western blot and laminin overlay at E15.5 and P0. a Shows an amido black stain of the transfer membrane indicating equivalent
loading in all lanes. b Western blot for IIH6 in the hindlimb muscle at E15.5 and P0, the relative molecular mass of α-dystroglycan in the wild type
is reduced compared to the adult mouse muscle and only residual IIH6 labelling was observed in FKRPKD. c At both E15.5 and P0, α-dystroglycan
was able to bind laminin in the wild type and no binding was observed in the FKRPKD
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development there is no compensatory increase in either
laminin α4 or α5 chains which is sometimes evident in
adult muscle. However, given that γ1 levels were similar
in FKRPKD and wild type, it remains a possibility that
another α-chain at least partially compensates for the re-
duction in laminin α2.
Primary myotube number and maturation is not altered
in FKRPKD muscle
Primary myotubes differ from secondary myotubes in
their size, number, development and expression of myosin
chain isoforms at E15.5 in the mouse [38, 39]. The major-
ity of slow myotubes initially express slow myosin [40]
consequently we initially evaluated the number of slow
myosin expressing myotubes in both the EDL and TA.
Using this criteria there were no significant differences be-
tween FKRPKD and wild type with respect to primary
myotube number (Fig. 5) indicating that reduced α-
dystroglycan glycosylation did not influence primary myo-
tube numbers. However, it was formally possible that an
alteration in the proportion of primary myotubes express-
ing slow myosin could have influenced this result, conse-
quently we next checked this parameter. As can be seen
from Fig. 5 this proportion decreased between E15.5 and
P0 in both the FKRPKD and wildtype as myosin compos-
ition changes with maturity depending on the muscle.
Nonetheless, the proportion of slow myosin expressing
myotubes was not significantly different between the
FKRPKD and wild type at either age. This indicates that
myotube maturation as determined by slow myosin heavy
chain expression was not altered by a reduction in α-
dystroglycan glycosylation and reduction in laminin α2.
Interestingly total fibre number in the TA was not signifi-
cantly different which contrasts with measurements taken
from midpoint along the limb at P0 shown in Fig. 6 where
there was a significant increase in the number of smaller
secondary myotubes in the FKRPKD relative to wild type.
Secondary myotubes initially form close to early neuro-
muscular junctions, this result may therefore reflect the
distance these sections were from the innervation zone.
Fig. 4 Immunolabelling of laminins α4, α5 γ1 and β1 at E15.5 and P0. Immunolabelling with chain-specific antibodies raised against laminin α4
(A, B, C, D), α5 (E, F, G, H) and γ1 (I, J, K, L), also indicated no clear reduction in FKRPKD relative to wild type at either E15.5 or P0. However, laminin
β1 (M, N, O, P) showed a subtle reduction in FKRPKD compared to wild type at E15.5 and P0
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Myotube cluster size at E15.5 is reduced but total fibre
number at P0 is increased across the mid belly region of
the muscle of FKRPKD relative to wild type
Substantial myoblast proliferation fuels the formation of
secondary myotubes. In view of the well recognized
mitogenic effects of laminin we next evaluated myotube
cluster size (one primary myotube and between one and
two secondary myotubes enclosed within a single base-
ment membrane) (Fig. 6a). Secondary myotubes initially
form in the midbelly region of the muscle and with mat-
uration extend the length of the muscle. In order to
make a precise comparison between wild type and
FKRPKD mice, our measurements were therefore under-
taken across the midbelly region of each muscle. At
E15.5 average myotube cluster size was significantly re-
duced in the TA but not the EDL of the FKRPKD relative
to wild type (Fig. 6b). Further analysis of the size distri-
bution of these clusters showed that in both muscles
there was a shift towards smaller clusters in the FKRPKD
relative to wild type (Fig. 6e). Since primary myotube
number was not significantly different these observations
were indicative of an alteration in secondary myogenesis
(Fig. 6c).
However, at P0, when many but not all secondary
myotubes had attained their own basal lamina, total fibre
number was significantly increased in the TA but not
the EDL of the FKRPKD compared to wild type at P0
(Fig. 6d). Analyses of the fibre size distribution showed
this to be due to a significantly higher number of smaller
fibres in the FKRPKD relative to wild type in the TA.
These counts were taken from sections calculated to
come from a region midway between the patella and
ankle joint of the hindlimb (Fig. 6f ).
FKRPKD mice show a reduced number of Pax7+ progenitor
cells in the TA muscle but not the EDL
In view of the increase in myotube cluster size we next
evaluated the expression of the transcription factor Pax7
which directs the differentiation of myogenic progenitor
cells down the muscle lineage (Fig. 7a, b). Counts were
made across the entire cross sectional area of the
muscle. Quantification of the number of Pax7+ nuclei
(expressed as the number per fibre) in the TA and EDL
at E15.5 and P0 is shown in Fig. 7c where it can be seen
that the number of Pax7+ nuclei per fibre was significantly
reduced in the FKRPKD TA at E15.5 and P0 (p = 0.0083
and p = 0.0157 respectively). Interestingly as with most of
the other quantitative analyses there was a trend for the
number of Pax7+ nuclei per fibre to be reduced in the
EDL but this did not achieve statistical significance. Whilst
Fig. 5 Slow myosin heavy chain expression. The majority of primary myotubes initially express slow myosin. Double labelling for slow myosin and
laminin/perlecan and counts of the entire muscle enabled a comparison of the percentage of primary myotubes that expressed slow myosin in
the TA and EDL at E15.5 and P0 (a, b, respectively). These analyses showed no significant differences in the percentage of slow myosin positive
fibres between wild type and FKRPKD indicating that primary myotube maturation was not altered by the reduction in α-dystroglycan glycosylation.
The total fibre number was also not significantly altered between wild type and FKRPKD (c, d). These counts were made on sections taken from the
mid-third section of the hindlimb
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Fig. 6 Fibre size and fibre numbers at E15.5 and P0. Double immunolabelling of slow myosin with laminin (a). At E15.5, many myotube clusters
are outlined by perlecan immunolabelling. These clusters consist of one primary and one or more smaller secondary myotubes (white arrow)
together with a number of secondary myotubes/fibres that have attained their own basement membrane (yellow arrows). Fibre size (area)
therefore refers to measurements of either myotube clusters or individual myotubes/fibres that have attained their own basement membrane.
There are many single myotubes enclosed within their own basement membrane in the FKRPKD at E15.5 which are less prominent in the wild
type (yellow arrows). At P0, a population of smaller myotubes/fibres were still enclosed within the primary myotube basement membrane, this
was more evident in the FKRPKD at P0 (red arrows). This was reflected by a significant reduction in fibre size in the TA muscle in the FKRPKD
compared to wild type (b). Fibre number (includes both myotube clusters and myotubes/fibres with their own basement membrane) at E15.5
was not significantly different between FKRPKD and wild type as was indicated in Fig. 5 where different sections along the mid-third of the muscle
length were analysed (c). A comparison of the size distribution graph clearly shows a shift towards smaller clusters in FKRPKD relative to wild type
at E15.5 attributed to a population of smaller secondaries attaining their own basement membrane (e). At P0, in sections taken at the midpoint
region of the limb fibre counts showed a significant increase in fibre number in the TA but not in the EDL of the FKRPKD compared to wild type
at P0 (d). The size distribution graph showed this to be due to an increase (p = 0.0547) in number of smaller fibres in the FKRPKD at P0 compared
to wild type in the TA (f)
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the majority of Pax7+ nuclei appeared to be within the
confines of the basal lamina at P0 - as delineated by lam-
inin immunolabelling, there were also many whose loca-
tion was ambiguous and so we could not accurately
quantify whether satellite cell homing itself had been dis-
turbed (Fig. 7a).
Interestingly the proportion of Pax7+/MyoD+ nuclei in
the FKRPKD TA was similar to wild type at P0 indicating
that myogenic differentiation was not delayed (Fig. 7e, f ).
However, the number of Pax7+ nuclei/fibre was signifi-
cantly reduced in the FKRPKD TA compared to wild type.
The number of Ki67 positive nuclei in the FKRPKD was
increased relative to wild type in the TA but not the EDL
at E15.5
In view of the reduction in Pax7 positive nuclei per fibre
we next sought to determine if cellular proliferation was
altered. Labelling for Ki67 (cell proliferation marker)
Fig. 7 Pax7 positive progenitor cell quantification. a shows double immunolabelling for Pax7 and laminin α2 in the TA, whilst b shows Ki67+ and
type IV collagen in the TA. White arrow indicates Pax7+ nuclei laying beneath the basal lamina whilst the yellow arrow shows Pax7+ nuclei outside
of the basal lamina (P0). However, many nuclei were in an ambiguous position and so only, the total number of Pax7+ nuclei was counted. These
counts expressed as the number of Pax7+ nuclei per fibre showed a significant reduction in the TA at E15.5 and P0 (p = 0.0083 and p = 0.0157,
respectively) in the FKRPKD relative to wild type (c). There was however, a significant increase (p = 0.0017) in the number of Ki67 (cell proliferation
marker) positive nuclei was observed in the TA of the FKRPKD at E15.5 but not at P0 (d). The proportion of Pax7 positive nuclei that were also
expressing MyoD was not significantly different between WT and FKRPKD (e). Immunolabelling for Pax7/MyoD is shown in (f). All immunolabelling
was carried out on serial transverse sections
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positive nuclei showed a significant increase (p = 0.0017)
in the TA of the FKRPKD but not the EDL at E15.5. At
birth these differences were no longer evident (Fig. 7d).
Myoblasts isolated from E15.5 embryos show reduced
myogenicity relative to wild type
Since our data indicated an alteration in secondary myo-
genesis reflected by the reduction in cluster size, we
undertook primary cell culture by isolating myoblasts at
E15.5, culturing these cells on a matrigel coated sub-
strate and allowing them to fuse. In agreement with the
reduction in myotube cluster size FKRPKD cells showed
a significant reduction in the fusion index (Fig. 8a).
Discussion
The secondary dystroglycanopathies are associated with
a wide clinical spectrum and a proportion of patients
show defects in the central nervous system in addition
to a muscular dystrophy. However, whilst neuronal mi-
gration defects together with pial basement membrane
defects occur prenatally, no previous reports have docu-
mented a prenatal onset for the disease in muscle. In
this study we hypothesized that, in view of the pivotal
role played by α-dystroglycan in basement membrane
organisation via its binding to ligands such as laminin
and perlecan [2], muscle development would be altered
such that fibre number, size and satellite cell number
would be reduced. Since we and others have previously
shown that the extent of α-dystroglycan glycosylation in-
creases with gestational age [25, 26] in both chick and
human muscle we further reasoned that the alterations
would be confined to the later stages of myogenesis.
Dystroglycan is essential for the initial binding of lam-
inin on the cell surface, whereas β1 integrins and perle-
can are subsequently required for laminin matrix
assembly [41]. In the present study we show that
organisation of the basement membrane as determined
by IIH6 and laminin α2 immunolabelling is altered by
E15.5 in the FKRPKD mice. This corresponds to a period
when myoblasts align and fuse along the surface of the
primary myotube and all are enclosed within a common
basal lamina [30]. Since the majority of primary myo-
tubes label for slow myosin heavy chain during the early
stages [42] we used this as a marker for primary myo-
tube formation. Primary myotube number was not sig-
nificantly different in either the TA or EDL and muscle
length as determined by the length of femur and tibia
was also not significantly different between the FKRPKD
or wild type littermates. Primary myotubes extend the
full length of the muscle from their earliest stages of for-
mation, and these observations therefore imply that early
myotube formation and differentiation are not altered by
defects in α-dystroglycan which are nonetheless present
by this stage. Indeed the proportion of slow myosin
heavy chain positive myotubes was not significantly dif-
ferent between wild type and FKRPKD and the expres-
sion patterns of fast MHC and developmental MHC was
also the same between the two groups at both E15.5 and
P0 which further suggested no obvious delay in matur-
ation (data not shown).
Myotube clusters are a characteristic of muscle devel-
opment mid gestation and they usually consist of a sin-
gle primary surrounded by one or more (depending on
the muscle) secondaries. Cluster size was found to be
significantly reduced in the TA but not the EDL at
E15.5. Since this parameter also showed a reduction in
the EDL which was not statistically significant we believe
that this time point represents the initial point of diver-
gence in the hindlimb muscles. The isolation of myo-
blasts from E15.5 hindlimbs showed a reduction in the
fusion index which together with the reduction in clus-
ter size suggests that a reduction in α-dystroglycan
Fig. 8 Myoblast fusion at E15.5. Myoblasts were isolated from the limbs at E15.5 for the further evaluation of reduction in cluster size that we
observed on transverse sections. The myogenic fusion index calculated by counting the proportion of nuclei contained within myotubes showed
a significant reduction in FKRPKD relative to wild type (a). Desmin immunolabelling further showed that the number of myotubes that formed
4–5 days after plating on Matrigel pre-coated coverslips was reduced in the FKRPKD (n = 6 wild type and 6 FKRPKD pups) (b)
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glycosylation impacts upon secondary myotube forma-
tion. Interestingly the number of Ki67 positive proliferat-
ing cells in the TA was increased at E15.5 but not P0
suggesting a transitory increase in the division of cells
not yet committed to the myogenic lineage. Given that
fibre number was slightly increased in the FKRPKD at
birth we assume that these cells do subsequently con-
tribute to fibre formation.
α-dystroglycan binds to LG domain containing pro-
teins of the extracellular matrix, including laminin and
perlecan. At E15.5 and P0, immunolabelling of laminin
α2 showed a reduction in FKRPKD mice relative to con-
trols. However, there was no apparent alteration in per-
lecan despite previous data showing the existence of a
trimolecular arrangement between α-dystroglycan, perle-
can and laminin, with perlecan binding to α-dystroglycan
indirectly [43]. This suggests that the incorporation of
laminin into the basement membrane during development
is more dependent on α-dystroglycan glycosylation than
perlecan, indeed the latter may have other binding part-
ners that are sufficient to facilitate its incorporation. La-
belling for type IV collagen (data not shown) displayed no
clear difference in FKRPKD mice relative to controls at ei-
ther E15.5 or birth showing that the other aspects of the
basement membrane were unaltered by the changes in α-
dystroglycan glycosylation. This is in contrast to the obser-
vations made in dystroglycan-null embryoid bodies where
the expression pattern of type IV collagen has been shown
to be disrupted [44]. This may reflect tissue-specific differ-
ences or may reflect the absence of both α and β-
dystroglycan in these cells.
Fibre number at birth showed a significant increase in
the FKRPKD TA but not EDL. This may be interpreted
in several ways namely that there is a more rapid
breakup of the clusters due to a weakened basement
membrane or alternatively an increase in branching of
the secondary myotubes. Branching is normally a re-
sponse to repeated injury/overloading [45]; however, this
has also been reported in dystrophin-deficient mdx and
caveolin-3-deficient mouse muscle during development
[46]. Indeed, it is possible that the lack of α-dystroglycan
glycosylation and the reduction in laminin α2 deposition
provide inappropriate cues for the early secondary and
tertiary myotubes and they branch.
Immunolabelling using an antibody to pan laminin
showed no apparent difference between the two groups
at both time points (Fig. 2b). Since pan laminin recog-
nises several laminin chains including β1 and γ1, this
observation strongly suggested that there might be a
partial compensation by other laminin isoforms prior to
birth for the loss of laminin α2. Laminin α5 is often up-
regulated in neuromuscular conditions and thought to
compensate for other α-chains. However, labelling with
antibodies to laminin α4, α1, α5 and γ1 failed to detect
any significant differences between FKRPKD and con-
trols. β1 on the other hand showed a subtle reduction
suggesting that the expression of laminin β1 was rather
influenced by the loss of laminin α2 and implies that β2
may partially compensate. However, real-time PCR indi-
cated no significant differences between FKRPKD and
wild type, although it was noted that there was a trend
for all to be reduced in the FKRPKD at E15.5. Indeed, it
could be that a reduction in expression levels of ligand
proteins is only manifested later on during development
when there has been a long-term reduction in the rele-
vant receptor.
Satellite cells are first evident around E17 and typically
identified using the paired box transcription factor, Pax7.
We have therefore referred to those nuclei expressing
Pax7 as progenitor cells rather than satellite cells. Whilst
they are traditionally thought to be derived from the so-
mites [47], there is now evidence to suggest that some
adult satellite cells may have alternative origins other
than the dermomyotome-derived Pax3+/Pax7+ progeni-
tor cells [48]. The dynamic interaction between the
extracellular matrix and the satellite cell plays a key role
in determining activity [48, 49] and in agreement with
this, we have previously shown the satellite cell niche to
be disturbed in the dystroglycanopathies [50]. A series of
transcription factors drive the progression from quies-
cence to activation, proliferation, and differentiation/
self-renewal. Quiescent satellite cells are characterised
by their expression of Pax7 and Myf5 but not MyoD or
Myogenin. The initiation of differentiation and fusion is
marked with the expression of Myogenin, which in con-
cert with MyoD will activate muscle-specific genes [48].
In the present study, we observed that the proportion of
activated progenitor cells (Pax7+/MyoD+) was not sig-
nificantly different in the TA between FKRPKD and wild
type at P0. This indicates that the differentiation itself
has not been delayed as is supported by the pattern of
myosin heavy chain expression. However, the absolute
number of Pax7 positive cells was decreased in the
FKRPKD TA relative to the wild type indicating that the
number of committed progenitor/satellite cells has been
reduced in the mutant which would be expected to com-
promise not only postnatal growth but also the regen-
erative capacity of the muscle.
Whilst there has been no previous detailed quantita-
tive assessment of muscle development in secondary
dystroglycanopathy mice, other work has suggested that
the severity of the phenotype may correlate with when
the expression of genes, such as that encoding for fuku-
tin, are deleted [35, 51]. Indeed, two groups previously
compared the two distinct conditional fukutin knock-out
(cKO) mice; the first, a myofibre-selective fukutin-
conditional knock-out (using the muscle creatine kinase
promoter to drive the deletion), which showed a mild
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muscular dystrophy whilst the second, deleted fukutin in
muscle precursor cells using the Myf5 promoter. The
earlier deletion resulted in a mouse with a more severe
form of muscular dystrophy. In the present paper as-
suming that fukutin and FKRP have a similar function,
the reduction in the number of Pax7 progenitor cells
identifies a possible mechanism behind previous obser-
vations of a regeneration disorder [35, 51]. Another in-
teresting aspect is the role of the CT carbohydrate
antigen {GalNAcβ1,4[NeuAcα2,3]Galβ1(-3GalNAc or
-4GlcNAc)} on α-dystroglycan which when expressed
outside its usual synaptic location leads to an accumula-
tion of satellite cells, reduced myofibre size and altered
neuromuscular junctions [52]. This work would seem to
indicate as did the work of Ross et al. [50] that alter-
ations in the glycosylation pattern of α-dystroglycan can
directly impact upon the stem or satellite cell population
with clear implications for postnatal muscle growth.
Conclusions
In summary, these data show for the first time a prenatal
onset with regard to the disease process and identify an
early reduction of laminin α2, reduction of myogenicity
and depletion of Pax7 positive progenitor cells which
would be expected to compromise subsequent postnatal
muscle growth and its ability to regenerate postnatally.
These findings are of significance to the development of
future therapies in this group of devastating conditions.
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